Boehringer Ingelheim’ Investigational Combination Witnesses Positive Results
Telmisartan and Amlodipine showed substantial and sustained 24-hour blood pressure lowering
Boehringer Ingelheim has announced that the company has presented telmisartan and amlodipine combination data at the 19th Scientific Meeting of the European Society of Hypertension, Milan, Italy.
The data demonstrated that treatment with an investigational combination of telmisartan and amlodipine showed substantial and sustained 24-hour blood pressure (BP) lowering. Also, it is well-tolerated in a range of patients with hypertension at risk of cardiovascular (CV) events.
The study included patients with Type 2 diabetes, obese patients, and those not controlled by amlodipine alone.
The telmisartan and amlodipine combination was investigated in a double-blind trial involving 1461 patients with hypertension. These patients were randomised to one of 16 treatment arms involving telmisartan 0mg, 20mg, 40mg or 80mg plus amlodipine 0mg, 2.5mg, 5mg or 10mg for eight weeks.
Related Insight
Suppliers Directory
CoreLab Partners - Centralised Medical Image Analysis and Cardiac Safety & Efficacy Services
CoreLab Partners, Inc provides our clinical trial sponsors best-in-class centralised cardiac safety & efficacy services and independent medical image assessment solutions; all designed to facilitate successful new drug development in the pharmaceutical, biotechnology and medical device market sectors.
Suppliers
Medical Research Network - Clinical Trial Support Organisation
The Medical Research Network (MRN) is a unique clinical trial support organisation (CTSO). The MRN has been involved in the conduct of over 50 clinical trials across a wide range of therapeutic areas, in particular oncology and rheumatology.
Suppliers
Medica Packaging - Leading Packaging Manufacturer for Pharmaceutical and Healthcare Industries
Medica Packaging is a leading packaging manufacturer of folding cartons, patient information leaflets, and printed labels for the pharmaceutical and healthcare industries. Medica understands that quality and security of product packaging are crucial ingredients for all involved in healthcare.
Suppliers
ETS Nederland BV - (Experimental Toxicology Services)
Experimental Toxicology Services (ETS) Nederland BV, based in Zutphen, the Netherlands, is a privately owned product development consultancy managed by Henk Tennekes, Ph.D.
Suppliers
Production & Manufacturing
Fine & Speciality Chemicals
Manufacturing
Process & Production
OTC
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Intelligence
Go Digital or Die
Published by NNIT
White Papers
Tips & Tricks - GPC/SEC: How to Validate a GPC/SEC System
Published by Polymer Standards Service
White Papers
Metathesis Catalysts
Published by Umicore Precious Metals Chemistry
White Papers
Buy the latest industry research online today!
Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Reports Buy online from $3500
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Reports Buy online from $3500
Comments may be moderated for spam, obscenities or defamation.